BENJAMIN J. ZESKIND - 23 Mar 2022 Form 4 Insider Report for Immuneering Corp (IMRX)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Issuer symbol
IMRX
Transactions as of
23 Mar 2022
Net transactions value
+$24,060
Form type
4
Filing time
24 Mar 2022, 16:39:25 UTC
Previous filing
01 Mar 2022
Next filing
14 Apr 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMRX Class A Common Stock Purchase $24,060 +3,000 +0.13% $8.02 2,257,352 23 Mar 2022 Direct F1
holding IMRX Class A Common Stock 894,927 23 Mar 2022 See Foonote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $7.92 to $8.10. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price.
F2 Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.